Select Publications
Journal articles
2022, 'Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris', Journal of the European Academy of Dermatology and Venereology, 36, pp. 852 - 855, http://dx.doi.org/10.1111/jdv.18318
,2022, 'Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)', Journal of the European Academy of Dermatology and Venereology, 36, pp. 1689 - 1704, http://dx.doi.org/10.1111/jdv.18220
,2022, 'Dupilumab-associated ocular manifestations: A review of clinical presentations and management', Survey of Ophthalmology, 67, pp. 1419 - 1442, http://dx.doi.org/10.1016/j.survophthal.2022.02.002
,2022, 'Evaluating skin colour representation in the Indian Journal of Dermatology, Venereology and Leprology', Indian Journal of Dermatology, Venereology and Leprology, 88, pp. 678 - 679, http://dx.doi.org/10.25259/IJDVL_947_2021
,2022, 'Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: Risk, outcome, vaccination, and beyond', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.987534
,2022, 'Allergic contact dermatitis to miconazole for nipple candidiasis', Contact dermatitis, 87, pp. 201 - 202, http://dx.doi.org/10.1111/cod.14125
,2022, 'Mental health, insomnia and suicidal ideation during treatment with apremilast', Australasian Journal of Dermatology, 63, pp. 403 - 404, http://dx.doi.org/10.1111/ajd.13864
,2022, 'Psoriasis and osteoporosis: a literature review', Clinical and Experimental Dermatology, 47, pp. 1438 - 1445, http://dx.doi.org/10.1111/ced.15174
,2022, 'Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study', Australasian Journal of Dermatology, 63, pp. 312 - 320, http://dx.doi.org/10.1111/ajd.13893
,2022, 'Pemphigoid gestationis and preeclampsia in a donor-egg IVF pregnancy', International Journal of Women's Dermatology, 8, http://dx.doi.org/10.1097/JW9.0000000000000026
,2022, 'How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey', JID Innovations, 2, http://dx.doi.org/10.1016/j.xjidi.2022.100129
,2022, 'Vaxzevria COVID-19 aşısı sonrasında gelişen şiddetli büllöz pemfigoid', Mucosa, 5, pp. 27 - 29, http://dx.doi.org/10.33204/mucosa.993581
,2022, 'Clinical features of chronic bullous dermatosis of childhood', Clinical and Experimental Dermatology, 47, pp. 873 - 881, http://dx.doi.org/10.1111/ced.15059
,2022, 'Critical Review of the Sentinel Lymph Node Surgery in Malignant Melanoma', Journal of Drugs in Dermatology, 21, pp. 510 - 516, http://dx.doi.org/10.36849/JDD.6198
,2022, 'An Analysis of Skin of Color Publications in the Journal of Drugs in Dermatology from 2018 to 2020', Journal of drugs in dermatology : JDD, 21, pp. 441 - 442, http://dx.doi.org/10.36849/JDD.6286
,2022, 'Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline*', British Journal of Dermatology, 186, pp. 620 - 632, http://dx.doi.org/10.1111/bjd.20809
,2022, 'Assessing quality of life in patients with autoimmune bullous diseases using the persian version of treatment of autoimmune bullous disease quality of life questionnaire finds similar effects in women as men', International Journal of Women's Dermatology, 8, http://dx.doi.org/10.1097/JW9.0000000000000004
,2022, 'Evaluation of skin of color content in Skin Research and Technology', Skin Research and Technology, 28, pp. 355 - 356, http://dx.doi.org/10.1111/srt.13105
,2022, 'Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: A cohort study', JAAD International, 6, pp. 68 - 76, http://dx.doi.org/10.1016/j.jdin.2021.09.003
,2022, 'Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study', Indian Journal of Dermatology, Venereology and Leprology, 88, pp. 177 - 183, http://dx.doi.org/10.25259/IJDVL_31_20
,2022, 'Purposeful inclusion of skin of colour in published literature for improved dermatology education: a call to action', Clinical and Experimental Dermatology, 47, pp. 409 - 410, http://dx.doi.org/10.1111/ced.14821
,2022, 'Biological medication in atopic dermatitis', Expert Opinion on Biological Therapy, 22, pp. 643 - 649, http://dx.doi.org/10.1080/14712598.2022.2026920
,2022, 'Proposed management algorithm for dupilumab-associated ocular side effects: a collaborative effort between dermatologists and ophthalmologists', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.18397
,2022, 'Three-Year Assessment of Diversity and Skin of Color Content in Dermatitis', Dermatitis, 33, pp. E6 - E7, http://dx.doi.org/10.1097/DER.0000000000000813
,2022, 'Training and Retaining Physician‒Scientists in Dermatology: Australia', JID Innovations, 2, http://dx.doi.org/10.1016/j.xjidi.2021.100074
,2022, '070 Treating Bullous Pemphigoid by Inhibiting FcRn: A Phase 2/3 Trial with Efgartigimod', Journal of Investigative Dermatology, 142, pp. S192 - S192, http://dx.doi.org/10.1016/j.jid.2022.09.079
,2022, '34650 Correlation between wound burden and procedural pain in patients with EB ≥4 years of age: An exploratory analysis from the EASE study', Journal of the American Academy of Dermatology, 87, pp. AB152 - AB152, http://dx.doi.org/10.1016/j.jaad.2022.06.641
,2022, 'LB970 Effect of Oleogel-S10 (birch triterpenes) on dressing change frequency and wound infection in epidermolysis bullosa: Analysis from the EASE study', Journal of Investigative Dermatology, 142, pp. B22 - B22, http://dx.doi.org/10.1016/j.jid.2022.05.992
,2021, 'Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers', International Journal of Women's Dermatology, 7, pp. 721 - 726, http://dx.doi.org/10.1016/j.ijwd.2021.08.007
,2021, 'Shedding light on the impact of hidradenitis suppurativa on women and their families: A focus of the International Journal of Women's Dermatology', International Journal of Women's Dermatology, 7, pp. 661 - 663, http://dx.doi.org/10.1016/j.ijwd.2021.08.005
,2021, 'State-of-the-art review of human autoimmune blistering diseases (AIBD)', Veterinary Dermatology, 32, pp. 524 - e145, http://dx.doi.org/10.1111/vde.13008
,2021, 'T-Cell-Driven Fibroinflammation Inducing Follicular Dedifferentiation in Alopecia Areata and IgG4-Modified Disease', American Journal of Dermatopathology, 43, pp. 955 - 961, http://dx.doi.org/10.1097/DAD.0000000000001992
,2021, 'Angiosarcoma presenting as unexplainable unilateral leg pain and purpuric toes', Medical Journal of Australia, 215, pp. 456, http://dx.doi.org/10.5694/mja2.51310
,2021, 'An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study', Experimental Dermatology, 30, pp. 1675 - 1685, http://dx.doi.org/10.1111/exd.14252
,2021, 'Assessment of published literature regarding skin of color in Pediatric Dermatology', Pediatric Dermatology, 38, pp. 1604 - 1605, http://dx.doi.org/10.1111/pde.14823
,2021, 'Evaluating diversity in Clinics in Dermatology: Diversity in clinics in dermatology: M. Sun et al.', Clinics in Dermatology, 39, pp. 1064 - 1066, http://dx.doi.org/10.1016/j.clindermatol.2021.07.010
,2021, 'Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey', Journal of the American Academy of Dermatology, 85, pp. 1161 - 1167, http://dx.doi.org/10.1016/j.jaad.2020.03.028
,2021, 'European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II', Journal of the European Academy of Dermatology and Venereology, 35, pp. 1926 - 1948, http://dx.doi.org/10.1111/jdv.17395
,2021, 'Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*', British Journal of Dermatology, 185, pp. 745 - 755, http://dx.doi.org/10.1111/bjd.20431
,2021, 'Assessment of skin of color and diversity and inclusion content of dermatologic published literature: An analysis and call to action', International Journal of Women's Dermatology, 7, pp. 391 - 397, http://dx.doi.org/10.1016/j.ijwd.2021.04.001
,2021, 'Embracing diversity in dermatology: Creation of a culture of inclusion in dermatologic publishing', International Journal of Women's Dermatology, 7, pp. 371 - 377, http://dx.doi.org/10.1016/j.ijwd.2021.08.001
,2021, 'European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I', Journal of the European Academy of Dermatology and Venereology, 35, pp. 1750 - 1764, http://dx.doi.org/10.1111/jdv.17397
,2021, 'Gdf6 knockdown in a family with multiple synostosis syndrome and speech impairment', Genes, 12, http://dx.doi.org/10.3390/genes12091354
,2021, 'Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey', Pediatric Dermatology, 38, pp. 1198 - 1201, http://dx.doi.org/10.1111/pde.14802
,2021, 'Pharmacist recommendations regarding topical steroid use may contradict the standard of care in atopic dermatitis: An international, cross-sectional study', JAAD International, 4, pp. 13 - 14, http://dx.doi.org/10.1016/j.jdin.2021.04.005
,2021, 'The impact of gender in mentor–mentee success: Results from the Women's Dermatologic Society Mentorship Survey', International Journal of Women's Dermatology, 7, pp. 398 - 402, http://dx.doi.org/10.1016/j.ijwd.2021.04.010
,2021, 'Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus', Frontiers in Medicine, 8, http://dx.doi.org/10.3389/fmed.2021.708071
,2021, 'Impact of COVID-19 on inpatient dermatology consults in an Australian tertiary hospital', Australasian Journal of Dermatology, 62, pp. 427 - 428, http://dx.doi.org/10.1111/ajd.13649
,2021, 'Are biosimilars for pemphigus safe?', Clinical and Experimental Dermatology, 46, pp. 942 - 943, http://dx.doi.org/10.1111/ced.14610
,2021, 'Individual patients’ risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab', Journal of the American Academy of Dermatology, 85, pp. e47 - e48, http://dx.doi.org/10.1016/j.jaad.2021.03.018
,